Stock PHXM PHAXIAM THERAPEUTICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.95 EUR 0.00% Intraday chart for PHAXIAM Therapeutics S.A. +1.03% -35.87%
Apr. 15 Phaxiam initiates trial in infective endocarditis CF
Apr. 15 PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus CI

Evolution of the average Target Price on PHAXIAM Therapeutics S.A.

Price target over the last 5 years

History of analyst recommendation changes

7e5d.g-HIggZkk0V3Enb7HXD8P9UbVRe3BHMOwCeSenuFmqw.0NeGyGogpxYPJAWVezqmDZ8sLW2BNBtYhm7oKR7B692zoo3PVzWnCjIrNw~0b1f096cf328144b2b2348ac7fe4143b

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.95 EUR
Average target price
6.85 EUR
Spread / Average Target
+132.20%
High Price Target
8 EUR
Spread / Highest target
+171.19%
Low Price Target
5.7 EUR
Spread / Lowest Target
+93.22%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. Consensus PHAXIAM Therapeutics S.A.